Science & Research
The neuroscience behind Haven™.
A mechanistically grounded approach to treating depression — built on published research in Rapid Neuroplasticity Therapy and perineuronal net biology.
How it works
The science of Rapid Neuroplasticity Therapy.
The adult brain remains plastic, but this plasticity is regulated by biological scaffolds called perineuronal nets. In depression, these structures act as a cage, locking neural circuits into rigid, negative patterns. When adaptation becomes impossible, suffering becomes chronic.
Haven™ delivers precise 60 Hz light stimulation through the eyes. This signal propagates through neuronal circuits, ultimately activating the brain's immune cells, called microglia. These cells are stimulated to transiently open perineuronal nets, allowing new, healthy neural connections to form while gradually reducing harmful ones.
This is not symptomatic relief. It is a mechanistically grounded intervention that addresses the structural basis of depression.
Visualised
Novel mechanism of action.
Watch how Rapid Neuroplasticity Therapy activates the brain's immune cells and is designed to restore neuroplasticity.
Key differentiators
What makes Haven™ different.
Non-invasive
Delivered through the eyes via a medical headset. No implants, no anesthesia.
Non-pharmaceutical
No drugs. No severe side effects. No dependency risk. No interaction with existing medications.
Rapid-acting
Early clinical data shows remission in two weeks, compared to 6–12 weeks for traditional antidepressants.
Mechanistically grounded
Built on published neuroscience from our founding research team. Not accidentally discovered. Designed with intent.
Clinical Program
Building the evidence base.
Syntropic Medical™'s clinical program spans three trials, four patents, and an expanding research pipeline. Our program is establishing that:
Depression is reversible, not just manageable.
Plasticity is the key to the therapeutic response.
Non-invasive neuromodulation can be precise, scalable, and effective.
Regulatory pathway: Haven™ is pursuing regulatory clearance, with clearance targeted for 2028.
~70%
remission rate in early studies
2 weeks
to remission
3 trials
active and completed
4 patent families
protecting our IP
4 indications
in our pipeline
2028
regulatory clearance target
Clinical Roadmap
Path to regulatory approval.
Three sequential clinical trials building the safety and efficacy evidence required for regulatory clearance, followed by a post-market programme to secure broad payer coverage.
Core Regulatory Approval Pathway
LUX
Phase IIa
São Paulo, Brazil
Outcomes — 2026
- –Safety demonstrated in controlled environment
- –Eye safety demonstrated
- –Early efficacy readouts
Trial completed: January 2026
NEON
Phase IIa
New York, USA
Outcomes — 2026
- –Home-use safety demonstrated
- –Placebo-controlled design
- –Early efficacy readouts
Final Data: Summer 2026
GLOW
Phase IIb
Multi-Centre
Outcomes — 2028
- –Confirmation of efficacy
- –Health economics data
- –Regulatory application
Final Data: 2028
Target
Regulatory Approval
Non-Significant Risk
Regulatory Clearance 2028
Beyond depression
A platform for Rapid Neuroplasticity Therapy.
Syntropic Medical™ is starting with Major Depressive Disorder because it is urgent and the unmet need is vast. But our technology creates a defensible platform for any disorder defined by maladaptive stability in neural circuits.
Syntropic's Rapid Neuroplasticity Therapy Mechanism is expanding with future indications.
Major Depressive Disorder
Primary indication · Active clinical program
Anxiety
ClinicalSleep
ClinicalPTSD
R&DResearch
Published research.
Get Involved
Rapid Neuroplasticity therapy for depression.
Join the clinical program. Partner with us.
Invest in the future of depression treatment.